TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies, specifically, relapsed and refractory non-Hodgkins lymphoma.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-04)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tg Therapeutics (TGTX US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-04)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Annual Report (Amendment) (Form 10-K/A | Period ending 2023-12-31)

Current Report (Form 8-K | Period ending 2024-08-02)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)